Drawing for RELEAZE

USPTO serial 79381898

RELEAZE

Reviewed by CopyMark Law Group

Reg. 8081465Status 700Registered
Filing date
Status date
Registration date
Dec 30, 2025
Examiner
CRUZADO, SAMANTHA LEE
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with RELEAZE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

AMY WRIGHT

AMY WRIGHT TAFT STETTINIUS & HOLLISTER, LLPONE INDIANA SQUARE, SUITE 3500INDIANAPOLIS, IN 46204UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
009apparatus and instruments for recording, transmitting, reproducing or processing sound, images or data; data processing equipment; blank electronic storage media; remote monitoring apparatus namely, electronic devices for remote monitoring the function of electronic pleural or peritoneal fluid drainage devices, not for medical purposes; computers, computer hardware and computer peripheral devices; downloadable and recorded computer software namely, downloadable and recorded computer software programs for monitoring and managing pleural fluid or peritoneal drainage, analyzing patient data, and facilitating communication between patients and healthcare providers for the treatment of pleural effusion or ascites; downloadable and recorded mobile application software namely, downloadable and recorded software applications for mobile devices that enable the remote monitoring and managing of pleural or peritoneal fluid drainage, provide real-time alerts, track drainage performance metrics such as fluid volume and flow rate, and allow data transmission to healthcare professionals for the management and treatment of pleural effusion or ascites; downloadable and recorded software relating to the delivery of healthcare, namely, downloadable and recorded software for use in the remote monitoring, management, and analysis of patient health data, specifically designed to support healthcare delivery systems for conditions requiring pleural or peritoneal fluid drainage; downloadable and recorded software for use with medical devices namely, downloadable and recorded software for integrating with medical devices, specifically pleural or peritoneal drainage systems, to enable the measurement, transmission, and analysis of drainage-related data, including pleural or peritoneal fluid volume, flow rate, and intra-pleural and peritoneal pressure, for use in the treatment and management of pleural effusion or ascites; downloadable and recorded software as a medical device (SaMD) namely, downloadable and recorded software that functions as a medical device to monitor and analyze pleural or peritoneal fluid drainage, detect abnormalities in drainage parameters, generate alerts for irregular conditions, and provide clinical decision support for the management of pleural effusion or ascites; downloadable and recorded software for use with medical patient monitoring equipment, in particular, for receiving, processing, transmitting and displaying patient data; downloadable electronic publications, namely, instructional manuals, guides, reports, and educational materials in the nature of books and articles relating to the use, management, and monitoring of pleural drainage systems, medical devices, and associated software for the treatment of pleural effusion or ascitesACTIVE—
010Surgical and medical apparatus and instruments, namely, devices for the drainage and management of pleural effusion and ascites, comprised primarily of catheters, drainage tubes, collection systems, for use in the treatment of pleural effusion and ascites, and other fluid management conditions; medical devices for the drainage, monitoring, and management of pleural effusion and ascites, namely drainage catheters and fluid collection systems comprised primarily of drainage tubes for medical purposes and also including electronic sensors, and integrated electronic monitoring apparatus for use in the treatment of pleural effusion and ascites, and other fluid management conditions; medical apparatus, equipment and instruments used in palliative care namely, pleural and peritoneal drainage systems comprised primarily of catheters, and portable fluid collection devices comprised of drainage catheters, and also including remote monitoring systems comprised of electronic devices for monitoring pleural effusion and ascites and providing symptom relief to patients in late-stage cancer care and with other chronic conditions; chest drainage devices for removal of fluids from the pleural and peritoneal cavity of patients; parts and structural fittings for the aforesaid goodsACTIVE—
042Scientific and technological services, namely, research, design and development of medical devices, remote monitoring systems, and software solutions for the diagnosis, treatment, and management of pleural effusion or ascites, and related palliative care conditions; medical research and development services, namely, medical research and development services in the field of pleural and peritoneal fluid management, specifically focusing on the creation, testing, and improvement of pleural and peritoneal drainage systems, medical devices, and associated monitoring technologies for the treatment of pleural effusion or ascites, and related palliative care conditions; industrial analysis and research services, relating to the performance, efficiency, and effectiveness of medical devices and technologies, specifically for pleural and peritoneal fluid drainage, remote monitoring systems, and software used in the management of pleural effusion or ascites; design services for medical devices, drainage systems, and electronic monitoring apparatus, including user interface and software design, specifically tailored to facilitate the management, monitoring, and treatment of pleural effusion or ascites, and related palliative care; Software as a Service (SAAS) featuring cloud-based software platforms for remote monitoring, data collection, and analysis of pleural fluid drainage parameters, including fluid volume, flow rate, and pressure, for use in the treatment and management of pleural effusion; Platform as a Service (PAAS) providing online platforms for medical professionals and healthcare providers to remotely access, analyze, and manage patient data related to pleural and peritoneal fluid drainage systems; computer software and hardware design and development; computer software and hardware design and development in the field of palliative care; computer software and hardware design and development for use with medical devices; computer software and hardware design and development for receiving, processing, transmitting and displaying patient data; technological consulting services in the field of medicine, medical devices and health care technology specifically relating to the development, implementation, and optimization of pleural and peritoneal drainage systems, remote monitoring technologies, and software solutions for managing pleural effusion or ascites, and improving palliative and chronic care outcomesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 23, 2026FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jul 6, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jul 6, 2026FIMPFINAL DISPOSITION PROCESSED—
Mar 30, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 26, 2026NREPNEW REPRESENTATIVE AT IB RECEIVED—
Dec 30, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Dec 30, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 11, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 11, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 5, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 9, 2025EXPTEXPARTE APPEAL TERMINATED—
Oct 9, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 11, 2025EXPIEX PARTE APPEAL-INSTITUTED—
Aug 11, 2025JURTJURISDICTION RESTORED TO EXAMINING ATTORNEY—
Aug 11, 2025EXAFEXPARTE APPEAL RECEIVED AT TTAB—
Aug 9, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 9, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 9, 2025ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Apr 12, 2025OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Mar 25, 2025OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 25, 2025OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Feb 11, 2025GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Feb 11, 2025GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 11, 2025CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Dec 24, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 23, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 23, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 15, 2024RFNTREFUSAL PROCESSED BY IB—
Jun 24, 2024RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 24, 2024RFRRREFUSAL PROCESSED BY MPU—
Jun 7, 2024RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 7, 2024RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
May 21, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 14, 2024DOCKASSIGNED TO EXAMINER—
Nov 11, 2023MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 7, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 26, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance